Inhibition of Fatty Acid Oxidation as a New Target To Treat Primary Amoebic Meningoencephalitis
Open Access
- 1 August 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (8)
- https://doi.org/10.1128/AAC.00344-20
Abstract
Primary amoebic meningoencephalitis (PAM) is a rapidly fatal infection caused by the free-living amoeba Naegleria fowleri. The amoeba migrates along the olfactory nerve to the brain, resulting in seizures, coma, and, eventually, death. Previous research has shown that Naegleria gruberi, a close relative of N. fowleri, prefers lipids over glucose as an energy source. Therefore, we tested several already-approved inhibitors of fatty acid oxidation alongside the currently used drugs amphotericin B and miltefosine. Our data demonstrate that etomoxir, orlistat, perhexiline, thioridazine, and valproic acid inhibited growth of N. gruberi. We then tested these compounds on N. fowleri and found etomoxir, perhexiline, and thioridazine to be effective growth inhibitors. Hence, not only are lipids the preferred food source for N. gruberi, but also oxidation of fatty acids seems to be essential for growth of N. fowleri. Inhibition of fatty acid oxidation could result in new treatment options, as thioridazine inhibits N. fowleri growth in concentrations that can be reached at the site of infection. It could also potentiate currently used therapy, as checkerboard assays revealed synergy between miltefosine and etomoxir. Animal testing should be performed to confirm the added value of these inhibitors. Although the development of new drugs and randomized controlled trials for this rare disease are nearly impossible, inhibition of fatty acid oxidation seems a promising strategy as we showed effectivity of several drugs that are or have been in use and that thus could be repurposed to treat PAM in the future.Funding Information
- European Molecular Biology Organization (Short-Term Fellowship #8453)
This publication has 45 references indexed in Scilit:
- Corifungin, a New Drug Lead against Naegleria, Identified from a High-Throughput ScreenAntimicrobial Agents and Chemotherapy, 2012
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJournal of Antimicrobial Chemotherapy, 2012
- Primary Amebic Meningoencephalitis Caused byNaegleria fowleri, Karachi, PakistanEmerging Infectious Diseases, 2011
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- The Genome of Naegleria gruberi Illuminates Early Eukaryotic VersatilityCell, 2010
- Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and In Vitro - In Vivo Correlation Data for Antifungal Drug Combinations against Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2010
- Effect of Therapeutic Chemical Agents In Vitro and on Experimental Meningoencephalitis Due to Naegleria fowleriAntimicrobial Agents and Chemotherapy, 2008
- A LIGHT MICROSCOPY STUDY OF THE MIGRATION OFNAEGLERIA FOWLERIFROM THE NASAL SUBMUCOSA TO THE CENTRAL NERVOUS SYSTEM DURING THE EARLY STAGE OF PRIMARY AMEBIC MENINGOENCEPHALITIS IN MICEJournal of Parasitology, 2000
- A Light Microscopy Study of the Migration of Naegleria fowleri from the Nasal Submucosa to the Central Nervous System during the Early Stage of Primary Amebic Meningoencephalitis in MiceJournal of Parasitology, 2000
- Thioridazine: a selective inhibitor of peroxisomal β‐oxidation in vivoFEBS Letters, 1985